Evidence-Based Guide

Yeast Infection

A physician's evidence-based guide to causes, symptoms, diagnosis, and the best treatments for vulvovaginal candidiasis in 2026, including what actually works and what does not.

What is the best treatment for a yeast infection in 2026?

A vaginal yeast infection (vulvovaginal candidiasis, or VVC) affects an estimated 75 percent of women at least once in their lifetime and is usually caused by Candida albicans.[1] First-line treatment in the CDC 2021 STI Treatment Guidelines is a short course of an azole antifungal, either a single 150 mg oral dose of fluconazole or an over-the-counter or prescription vaginal azole such as miconazole, clotrimazole, or terconazole; azoles relieve symptoms and clear cultures in 80 to 90 percent of patients who complete therapy.[1] Fewer than 5 percent of women develop recurrent infection (three or more episodes in less than a year, by the CDC definition), which is managed with longer suppression using weekly fluconazole, as in the landmark Sobel NEJM trial.[1] Newer prescription agents, ibrexafungerp and oteseconazole, are contraindicated in pregnancy, and oteseconazole is approved only for women who are not of reproductive potential.[25][26] Self-diagnosis is unreliable: in one study, fewer than 35 percent of women who assumed they had a yeast infection actually did.[5] A licensed clinician, in person or via telehealth, can confirm the diagnosis and recommend the right treatment.
Medically reviewed by Parth Bhavsar, MD. Updated September 8, 2026.

Key Takeaways

  • A yeast infection is overgrowth of the fungus Candida in the vagina, and an estimated 75 percent of women will have at least one episode in their lifetime.[1] It is not usually acquired through sex, and the CDC does not recommend treating sex partners.[1]
  • Uncomplicated infection responds well to a single 150 mg oral dose of fluconazole or a short course of a vaginal azole; azoles relieve symptoms and clear cultures in 80 to 90 percent of patients who complete therapy.[1]
  • Self-diagnosis is wrong more than half of the time, so confirm the diagnosis before treating, especially if symptoms persist or recur.[5]
  • Recurrent infection (three or more episodes in less than a year) affects fewer than 5 percent of women and is managed with long-term suppression, most classically weekly fluconazole for six months, which kept about 91 percent of women episode-free at six months versus 36 percent on placebo.[1][6]
  • Newer prescription options approved by the FDA since 2021, ibrexafungerp (Brexafemme) for acute and recurrent infection and oteseconazole (Vivjoa) for recurrent infection, are contraindicated in pregnancy, and oteseconazole is approved only for women who are not of reproductive potential.[25][26]
  • Typical features are vulvar itching, soreness, and thick, curdy discharge with a normal vaginal pH below 4.5; a pH above 4.5 is common with bacterial vaginosis or trichomoniasis instead.[1][27]
  • See a clinician if symptoms persist after an over-the-counter treatment or return within 2 months, because the CDC advises evaluation and testing then, and frequent yeast infections can be a symptom of diabetes.[1][29]
Editorial medical illustration representing a vaginal yeast infection
Vulvovaginal candidiasis, commonly called a yeast infection: an evidence-based overview from the TeleDirectMD medical team.

Here is the single most important fact about yeast infections before anything else: they are common, they are usually easy to treat, and they are frequently misdiagnosed, both by patients and by the shelf of products at the drugstore. Many women who reach for an over-the-counter antifungal do not actually have a yeast infection. In a study of 95 symptomatic women who bought an over-the-counter antifungal for a presumed yeast infection, examination and laboratory testing confirmed a yeast infection in only 33.7 percent. The rest had bacterial vaginosis, mixed vaginitis, trichomoniasis, another diagnosis, or normal findings.[5]

This guide is a physician's walk through what a yeast infection actually is, what causes it, how it is correctly diagnosed, the treatments that work, the newer medicines approved since 2021, and the home remedies that do not hold up to scrutiny. Clinical claims are cited to the CDC treatment guideline, FDA drug labels, and peer-reviewed studies.

What Is a Yeast Infection?

A yeast infection, more precisely called vulvovaginal candidiasis (VVC), is an overgrowth of Candida, a fungus that many healthy women carry in the vagina without symptoms. When the balance between Candida and the vaginal environment is disturbed, the fungus can multiply, shift from its yeast form to invasive filamentous (pseudohyphal and hyphal) forms, and trigger inflammation of the vulva and vagina.[1][2][7]

Candida albicans causes most infections, but other species cause some, with estimates of up to 19 percent. Non-albicans species, especially Candida glabrata, are being identified more often, and they matter because most are less sensitive to the usual azole antifungals.[1][22][2][7]

The condition is extremely common. An estimated 75 percent of women will have at least one episode of VVC, and 40 to 45 percent will have two or more. The CDC defines recurrent infection as three or more symptomatic episodes in less than a year and estimates that it affects fewer than 5 percent of women.[1] Estimates vary with the definition: in a 2013 internet survey of 6,000 women in six countries, 9 percent overall reported a 12-month period with four or more infections.[4] A systematic review by Denning and colleagues estimated that recurrent vulvovaginal candidiasis, defined as four or more episodes a year, affects about 138 million women worldwide each year.[3]

How common are yeast infectionsLifetime pattern of vulvovaginal candidiasis in womenAt least one episode in lifetime75%Two or more episodes40 to 45%Recurrent (3+ episodes in a year)Under 5%Source: CDC STI Treatment Guidelines, 2021
Lifetime risk of vulvovaginal candidiasis builds in stages: most women experience at least one episode, while a small subset develops recurrent disease.[1]

What Causes a Yeast Infection?

The vagina is normally dominated by Lactobacillus bacteria that keep it acidic. Disruptions of this microbiome, from antibiotics, hormonal fluctuations, or sexual activity, can lead to fungal overgrowth, and so can conditions that weaken the immune defenses that contain the fungus.[7][2]

Antibiotics

A major contributor. Antibiotics disrupt the protective vaginal microbiota, and recurrent infection can be secondary to frequent antibiotic use.[7][1]

Elevated estrogen

Elevated estrogen promotes Candida colonization, whether it comes from pregnancy, the second half of the menstrual cycle (the luteal phase), combined oral contraceptives, or menopause hormone therapy. Across a woman's lifespan, how often VVC occurs tracks closely with estrogen levels.[7][2]

Diabetes

Uncontrolled diabetes raises vaginal glucose levels, which promotes yeast overgrowth, and also impairs immune function. SGLT2 inhibitors, a class of diabetes medicines that pass sugar into the urine, also increase the risk of recurrent infection.[7] The CDC lists frequent yeast infections among the symptoms of diabetes.[29]

Weakened immunity

Immunosuppression from untreated HIV, chemotherapy, corticosteroids, or other immunosuppressive medicines raises the risk of infection, and women with these conditions may not respond as well to short courses of treatment.[7][1]

Lifestyle and other factors

Reviews list behavioral factors such as oral contraceptives, intrauterine devices, spermicides and condoms, and some hygiene, clothing, and sexual habits as possible contributors.[2] Tight synthetic clothing may trap heat and moisture, and overwashing and feminine hygiene products can dry and damage vulval skin.[7] In one study of 65 women with recurrent infection on maintenance therapy, wearing pantyliners or pantyhose, consuming cranberry juice or acidophilus-containing products, a history of bacterial vaginosis, and age under 40 were linked to recurrence.[17] Host factors described in reviews include pregnancy, hormone replacement, uncontrolled diabetes, immunosuppression, antibiotics, and glucocorticoid use.[2]

Yeast Infection Symptoms

Typical symptoms and signs include the following, although none is specific to a yeast infection:[1][7]

  • Vulvar and vaginal itching (pruritus)
  • Burning of the vulva, vagina, and sometimes around the urethra
  • Thick, white, clumpy discharge, often described as curdy or cottage-cheese-like
  • Redness and swelling of the vulva (erythema and edema)
  • Pain during sex (dyspareunia) and discomfort with urination, which is usually external burning as urine touches inflamed skin rather than internal urgency

Odor is a useful clue: a thin discharge with a fishy (amine) odor points instead toward bacterial vaginosis, and an amine odor can also occur with trichomoniasis.[27][28]

How Is a Yeast Infection Diagnosed?

Diagnosis combines symptoms and an examination with simple office testing: the pH of vaginal fluid and a microscope check for yeast, with culture or PCR testing when needed.[1][7]

Vaginal pH. In a yeast infection, the vaginal pH stays in the normal range, below 4.5. In bacterial vaginosis and trichomoniasis, an elevated pH above 4.5 is common, so the measurement helps separate the most commonly confused conditions.[1][27]

Microscopy. A sample of discharge mixed with saline or 10 percent potassium hydroxide (KOH) is examined under a microscope. KOH breaks down cell material that can hide the yeast, and finding budding yeast, hyphae, or pseudohyphae supports the diagnosis in a woman with symptoms.[1] Microscopy is imperfect, though: in a 1995 emergency department study of 71 women, saline, KOH, and methylene blue preparations were only moderately accurate compared with culture, with a significant share of false-negative and false-positive results.[20]

Culture or DNA (PCR) testing is recommended for complicated infections, including recurrent and severe cases, to confirm the diagnosis and identify non-albicans species, and culture with susceptibility testing should be considered for women who remain symptomatic. A culture that grows Candida in a woman without symptoms is not a reason to treat.[1]

Many women who self-diagnose and use an over-the-counter product do not have a yeast infection, and the authors of that study concluded that ready access to these products delays correct diagnosis for a substantial number of women.[5] The CDC advises clinical evaluation and testing for anyone whose symptoms persist after an over-the-counter product or return within 2 months of treatment.[1]

Yeast Infection vs BV and Other Vaginitis

Three conditions cause most vaginal discharge and irritation: yeast infection, bacterial vaginosis (BV), and trichomoniasis. They are treated with entirely different medicines, so telling them apart matters. The table below summarizes the distinguishing features.

FeatureYeast infection (VVC)Bacterial vaginosis (BV)Trichomoniasis
Predominant symptomItching and burningMild or no discomfortIrritation, soreness
DischargeThick, white, clumpy, no odorThin, gray-white, fishy odorFrothy, yellow-green
Vaginal pHBelow 4.5 (normal)Above 4.5Above 4.5
CauseCandida fungusBacterial overgrowthParasite (T. vaginalis)
Key treatmentAzole antifungal (vaginal azole or oral fluconazole)Metronidazole or clindamycinMetronidazole or tinidazole
Sexually transmittedNoNot strictly, but associated with sexYes

For a full side-by-side breakdown of how to tell a yeast infection from BV, see our dedicated guide on yeast infection vs BV and the companion bacterial vaginosis guide. Vaginal dryness, common after menopause, can also cause burning and irritation and belongs in the differential; see the vaginal dryness treatment guide.

What's Changed 2024 to 2026

Three developments have updated the picture for patients and clinicians:

  • New FDA-approved oral antifungals. Ibrexafungerp (Brexafemme), approved in 2021, was the first oral non-azole for VVC.[22] In its phase 3 trial it outperformed placebo, with clinical cure in 50.5 percent versus 28.6 percent at the test-of-cure visit (day 11, plus or minus 3 days).[8] Oteseconazole (Vivjoa), approved in 2022, is a newer azole indicated to reduce recurrent infection only in women who are not of reproductive potential.[25]
  • Monthly ibrexafungerp for prevention. In the 2025 CANDLE trial, women with recurrent infection took one day of ibrexafungerp (300 mg twice) every 4 weeks for 6 treatments after fluconazole induction; 70.8 percent had no mycologically proven recurrence by the test-of-cure visit, versus 58.5 percent on placebo.[10] It offers an alternative to weekly fluconazole, but it is contraindicated in pregnancy, and the label advises effective contraception throughout the 6-month course and for 4 days after the last dose.[7][26]
  • Growing attention to azole resistance. A 2026 state-of-the-art review notes that recurrence and resistance are frequent, and a 2024 review describes the rising prevalence of resistant species, with boric acid, nystatin, and the newer agents among the alternatives.[7][13]

Which Treatment Is Right for You

Treatment choice depends on whether the infection is classified as uncomplicated or complicated, a distinction used in the CDC treatment guideline.[1]

ScenarioDefinitionRecommended approach
Uncomplicated VVCSporadic or infrequent, mild to moderate, likely C. albicans, in a woman who is not immunocompromisedAny recommended vaginal azole course (from a single application to 7 days, or 7 to 14 days for clotrimazole 1 percent cream) or a single 150 mg oral fluconazole dose[1]
Severe VVCExtensive vulvar erythema, edema, excoriation, and fissuresVaginal azole for 7 to 14 days or fluconazole 150 mg as two doses, the second 72 hours after the first[1]
Recurrent VVCThree or more symptomatic episodes in less than a yearInitial therapy (7 to 14 days of vaginal azole, or fluconazole 100, 150, or 200 mg on days 1, 4, and 7), then weekly oral fluconazole for 6 months[1][6]
Non-albicans or azole-resistantC. glabrata or other non-albicans species7 to 14 days of a non-fluconazole azole; if it recurs, boric acid 600 mg in a vaginal gelatin capsule once daily for 3 weeks, with specialist referral if symptoms recur[1][12][13]
PregnancyAny episode during pregnancyA vaginal azole for 7 days only; no oral fluconazole[1]

Treatment: The Evidence

The mainstay of treatment is the azole class of antifungals. They come as vaginal creams, ointments, and suppositories (clotrimazole, miconazole, and tioconazole over the counter; butoconazole and terconazole by prescription) and as the oral option fluconazole.[1]

Oral fluconazole 150 mg as a single dose is the CDC's recommended oral regimen for uncomplicated infection.[1] In a phase 3 single-arm study of 157 women in Japan, one 150 mg dose produced clinical cure in 81.6 percent at day 28.[16] A 2025 network meta-analysis of randomized trials found single-dose fluconazole slightly more effective than multiple-day topical therapy for early clinical cure, with no significant difference in late clinical cure.[14] It should not be used in pregnancy.[1]

Topical azoles act locally without significant systemic absorption, and they are the only treatment the CDC recommends in pregnancy.[7][1] Clotrimazole is available over the counter in 3-day and 7- to 14-day courses and miconazole in 1-day, 3-day, and 7-day courses, while terconazole 0.4 percent or 0.8 percent cream is prescription only. Longer courses are recommended for severe infection (7 to 14 days) and in pregnancy (7 days).[1]

Ibrexafungerp is an oral triterpenoid antifungal (not an azole) that inhibits glucan synthase, an enzyme needed to build the fungal cell wall. For an acute infection it is taken as 300 mg (two 150 mg tablets) twice, about 12 hours apart, for one day.[26] In its phase 3 trial it produced clinical cure in about half of treated women versus 28.6 percent on placebo.[8] It is most useful for women with azole allergy, non-albicans or azole-resistant yeast, or other reasons to avoid azoles, such as drug interactions.[22] It is contraindicated in pregnancy, so the label advises confirming that a woman of reproductive potential is not pregnant before starting it and using effective contraception during treatment and for 4 days after the last dose.[26]

Oteseconazole is a long-acting oral azole approved to reduce recurrent VVC only in women with a history of recurrent infection who are not of reproductive potential, meaning postmenopausal or permanently infertile (for example, after tubal ligation or hysterectomy). It is contraindicated in anyone of reproductive potential, in pregnancy, and during breastfeeding, because of embryo-fetal toxicity risk and a drug exposure window of roughly 690 days. The label gives two regimens, both taken with food: oteseconazole alone (600 mg on day 1, 450 mg on day 2, then 150 mg once a week for 11 weeks starting on day 14), or fluconazole 150 mg on days 1, 4, and 7, then oteseconazole 150 mg daily on days 14 through 20, then 150 mg once a week for 11 weeks starting on day 28.[25] In its phase 3 trials, recurrence through week 48 was 6.7 and 3.9 percent with oteseconazole versus 42.8 and 39.4 percent with placebo after fluconazole induction.[9] An earlier phase 2 trial in acute infection used 3-day courses, not a single dose, and its cure rates were not significantly different from single-dose fluconazole; oteseconazole is not FDA-approved to treat a single acute episode.[11][7]

Single-dose fluconazole 150 mg: results at day 28Phase 3 single-arm study in Japan, 157 women treated (modified intent-to-treat analysis)02040608010081.6%Clinical cure95.9%Cure or improvement85.9%Mycological eradicationSource: Mikamo 2015
Day 28 outcomes after one 150 mg dose of fluconazole in a single-arm phase 3 study; there was no comparison group.[16]

Comparison: Topical Azoles vs Oral Fluconazole

OptionRoute / dosingAvailabilityTypical cure rateNotes
Fluconazole 150 mgOral, single dosePrescription (generic)80 to 90 percent[1]Most convenient; not for use in pregnancy[1]
MiconazoleVaginal, 1, 3, or 7 daysOTC80 to 90 percent[1]Messy but effective; 7-day course is a pregnancy option[1]
ClotrimazoleVaginal, 3 days or 7 to 14 daysOTC80 to 90 percent[1]Common first choice; 7-day course is a pregnancy option[1]
TerconazoleVaginal, 3 or 7 daysPrescription80 to 90 percent[1]Strong topical option
IbrexafungerpOral, 2 doses over 1 dayPrescriptionClinical cure about 50 percent[8]Non-azole oral alternative; contraindicated in pregnancy[26]

A 2025 network meta-analysis of 50 randomized trials (7,208 participants) found that all the treatments studied were highly efficacious (above 75 percent) compared with placebo. Single-dose fluconazole was slightly more effective than multiple-day topical therapy for early clinical cure, with no significant difference in late clinical cure, and the authors judged a strict ranking of treatments probably inappropriate.[14]

How Long Does a Yeast Infection Last?

Precise timelines come from small studies. In a 1992 pilot trial of 22 women comparing one 200 mg dose of fluconazole with 3 days of terconazole suppositories, symptom relief began on average about 2 days after starting treatment, and symptoms resolved completely after about 6 to 7 days.[15] In a 2024 trial in 96 pregnant women, the mean time to clinical cure after a single vaginal suppository was about 3 days.[24] Anyone whose symptoms persist after an over-the-counter product, or return within 2 months, should be evaluated and tested.[1]

Days to symptom relief in a small trialMean days after starting treatment, 22 women, fluconazole 200 mg once vs terconazole 80 mg suppository for 3 days024682.4 daysFluconazole:relief begins1.8 daysTerconazole:relief begins6.1 daysFluconazole:complete relief6.6 daysTerconazole:complete reliefSource: Slavin 1992
Mean days to the start of symptom relief and to complete relief in a small randomized pilot trial; the differences between treatments were not statistically significant.[15]

Recurrent Yeast Infections

The CDC defines recurrent vulvovaginal candidiasis as three or more symptomatic episodes in less than a year. Most women with recurrent infection have no apparent predisposing or underlying condition, while in others it is linked to frequent antibiotic use, diabetes, or other host factors.[1] Because no treatment fully eradicates Candida from the body, symptoms recur in about half of patients who stop suppressive treatment.[7]

The best-established management is induction treatment to clear the current episode, followed by maintenance suppression. In the landmark 2004 New England Journal of Medicine trial by Sobel and colleagues, women first received three 150 mg doses of fluconazole 72 hours apart, then weekly oral fluconazole 150 mg or placebo for six months. Weekly fluconazole kept 90.8 percent of women free of recurrence at six months, compared with 35.9 percent on placebo. After treatment stopped, the share still disease-free fell to 42.9 percent at 12 months (21.9 percent with placebo), underscoring that suppression controls rather than cures the tendency.[6] The CDC lists 100, 150, or 200 mg of fluconazole weekly for 6 months as the maintenance regimen.[1]

For women who relapse despite weekly fluconazole, or who have azole-resistant or non-albicans yeast, options include boric acid vaginal capsules, nystatin, monthly ibrexafungerp, oteseconazole for women who are not of reproductive potential, and specialist evaluation.[12][13][25][26][1] Our recurrent yeast infection guide covers this in full depth.

Side Effects and Safety

Topical azoles usually cause no systemic side effects, although local burning or irritation can occur.[1]

In studies of single-dose fluconazole 150 mg for vaginal infection, the most common treatment-related side effects were headache (13 percent), nausea (7 percent), and abdominal pain (6 percent), and liver abnormalities have been observed during fluconazole treatment.[21] Fluconazole interacts with a number of medicines: it can raise prothrombin time with warfarin-type anticoagulants, increase the risk of muscle injury with statins (HMG-CoA reductase inhibitors), and raise phenytoin levels, and it must not be combined with some QT-prolonging drugs such as erythromycin, pimozide, and quinidine.[21] In pregnancy, the FDA label notes that epidemiological studies suggest a potential risk of miscarriage and congenital abnormalities after 150 mg taken as a single or repeated dose in the first trimester, and the CDC advises against using it in pregnancy.[21][1]

The CDC does not recommend treating sex partners, because uncomplicated yeast infection is not usually acquired through sex and data do not support partner treatment.[1]

Yeast Infection in Pregnancy

Elevated estrogen during pregnancy promotes Candida colonization.[7] The CDC recommends only topical azoles, applied for 7 days, in pregnancy and advises against oral fluconazole, even a single 150 mg dose, because of possible associations with miscarriage and congenital anomalies.[1] Ibrexafungerp and oteseconazole are contraindicated in pregnancy, and boric acid is contraindicated because of a lack of safety data.[26][25][7] In a randomized trial in 96 pregnant women, a single sertaconazole 300 mg vaginal suppository and a single clotrimazole 500 mg suppository had comparable clinical and microscopic cure rates, with no side effects reported.[24] A 2024 hospital study of 317 pregnant women in Ethiopia found vaginal candidiasis in 26.8 percent, and its isolates showed resistance to fluconazole, ketoconazole, and clotrimazole, so the authors urged treatment guided by susceptibility testing.[23]

Prevention

Evidence-based prevention focuses on the risk factors you can change:

  • Use antibiotics only when needed. Unnecessary antibiotic courses disrupt the vaginal microbiota and promote yeast overgrowth.[7]
  • Keep diabetes controlled. In people with high blood sugar, the risk of both new and recurrent genital yeast infection rises, which makes glucose control a key part of management.[30]
  • Skip douching and scented products. Overwashing and feminine hygiene products can dry and damage vulval skin, and a 2026 review advises against douching.[7]
  • Wear breathable clothing. Cotton underwear and avoiding tight synthetic clothing may help, since tight synthetic fabrics may trap heat and moisture.[7]
  • Be cautious about probiotics. A Cochrane review found that adding probiotics to antifungal treatment may improve short-term cure and lower relapse at one month, but the evidence was low or very low quality and showed no long-term benefit, and a 2026 review concludes that the best-designed studies do not support probiotics.[19][7]

What Doesn't Work

Several popular remedies lack evidence or can make things worse:

  • Douching with anything. No douche treats yeast, and a 2026 review advises against washing inside the vagina.[7]
  • Yogurt or other probiotics as a treatment. Despite folklore, the CDC states that no substantial evidence supports using probiotics to treat yeast infections.[1]
  • Garlic cloves inserted vaginally. Not proven effective and can cause burns or chemical irritation.
  • Apple cider vinegar. No clinical evidence, and vinegar is more likely to irritate inflamed tissue than to help.
  • Tea tree oil. Has some laboratory activity against Candida but little clinical trial support and can cause contact irritation.

For a detailed, sourced breakdown of what the evidence says about these and other home approaches, see the yeast infection home remedies guide.

Red Flags: When to Contact a Clinician

See a clinician rather than self-treating when any of these apply:

  • This is your first suspected yeast infection
  • Symptoms do not improve within a few days of over-the-counter treatment
  • You have a fever, chills, pelvic pain, or a foul-smelling discharge
  • Infections return repeatedly, three or more times in a year
  • You are pregnant or breastfeeding
  • You have diabetes, HIV, or another immunocompromising condition, or take immunosuppressive medicines
  • You have pain with urination that feels internal, flank pain, or any symptom suggesting a urinary tract infection or pelvic inflammatory disease

These patterns can point to a resistant or non-albicans infection, an undiagnosed condition such as diabetes, or a different diagnosis, because yeast infection symptoms overlap with those of other conditions.[1][29][7]

Frequently Asked Questions

A yeast infection typically causes redness and swelling of the vulva, sometimes with cracks in the skin, and a thick, white, curdy discharge. Itching, soreness, and burning with urination are typical.[1][7] Discharge from bacterial vaginosis, by contrast, is thin and milky with a fishy odor.[28]

Yes, uncomplicated infection can be treated with over-the-counter clotrimazole, miconazole, or tioconazole.[1] But confirm that it is actually a yeast infection first: in one study, about two thirds of women who self-diagnosed were wrong, so if this is a first episode or symptoms are unusual, see a clinician.[5]

In a small trial, symptom relief began about 2 days after starting treatment and was complete after about 6 to 7 days.[15] If symptoms persist after an over-the-counter treatment or come back within 2 months, see a clinician for evaluation and testing.[1]

Reliable figures on how often an untreated symptomatic infection clears by itself are not available in the sources reviewed here. About 10 to 20 percent of women carry Candida in the vagina, and finding it without symptoms is not a reason to treat. When symptoms are present, azole treatment relieves symptoms and clears cultures in 80 to 90 percent of patients who complete it.[1]

No. Yeast infection is not classified as a sexually transmitted infection, and the CDC does not recommend treating sex partners because data do not support it. Many women carry Candida in the vagina without symptoms, and infection develops when conditions change.[1][7]

Yes. Men can develop Candida balanitis, with red areas on the head of the penis and itching or irritation, and a minority of male partners of women with yeast infections have it.[1] It occurs almost exclusively in uncircumcised men, and diabetes, especially when poorly controlled, raises the risk, as do antibiotics, corticosteroids, and immunosuppression.[30]

Recurrent infection can be idiopathic or linked to frequent antibiotic use, diabetes, or other host factors, and non-albicans species are found in 10 to 20 percent of women with recurrent infection.[1] Relapse is common after a first course of maintenance fluconazole, and ongoing maintenance remains the most effective option, so persistent recurrence warrants evaluation, testing, and often long-term suppressive therapy.[18][1]

Yes, with a vaginal azole such as clotrimazole or miconazole cream used for 7 days, which is the only type of treatment the CDC recommends in pregnancy. Oral fluconazole should not be used in pregnancy, even as a single dose.[1] Ibrexafungerp and oteseconazole are contraindicated in pregnancy.[26][25] Always discuss treatment with your obstetrician.

Yes. In a phase 3 study, a single 150 mg dose of oral fluconazole produced clinical cure in 81.6 percent of women by day 28,[16] and a 2025 network meta-analysis found it slightly more effective than multiple-day topical therapy for early clinical cure.[14] It should not be used in pregnancy.[1]

Evidence on diet is limited: a 2026 review notes that high sugar intake has been linked to yeast infection mainly in people with diabetes, with limited evidence in those without diabetes. Stress is not among the risk factors that review describes. Documented risk factors include antibiotics, diabetes, high-estrogen states such as pregnancy, and immune suppression.[7][2]

The evidence is weak. A Cochrane review found that probiotics added to antifungal treatment may improve short-term cure and lower relapse at one month, but the evidence was low or very low quality and did not show long-term benefit.[19] The CDC finds no substantial evidence for probiotics as a treatment, so they should not replace antifungal therapy.[1]

References

  1. Centers for Disease Control and Prevention. Vulvovaginal Candidiasis. Sexually Transmitted Infections Treatment Guidelines, 2021. Last reviewed July 22, 2021. Accessed November 7, 2026. CDC guideline page
  2. Gonçalves B, Ferreira C, Alves CT, et al. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. Crit Rev Microbiol. 42(6):905-927. Published online December 21, 2015. doi:10.3109/1040841X.2015.1091805
  3. Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis. 2018;18(11):e339-e347. doi:10.1016/S1473-3099(18)30103-8
  4. Foxman B, Muraglia R, Dietz JP, et al. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Low Genit Tract Dis. 2013;17(3):340-345. doi:10.1097/LGT.0b013e318273e8cf
  5. Ferris DG, Nyirjesy P, Sobel JD, et al. Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet Gynecol. 2002;99(3):419-425. doi:10.1016/s0029-7844(01)01759-8
  6. Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med. 2004;351(9):876-883. doi:10.1056/NEJMoa033114
  7. Rautemaa-Richardson R, Sobel JD, Stone N, et al. State-of-the-Art Review: Managing Vulvovaginal Candidiasis. Clin Infect Dis. 2026;82(3):371-382. doi:10.1093/cid/ciaf673
  8. Schwebke JR, Sobel R, Gersten JK, et al. Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303). Clin Infect Dis. 2022;74(11):1979-1985. doi:10.1093/cid/ciab750
  9. Sobel JD, Donders G, Degenhardt T, et al. Efficacy and Safety of Oteseconazole in Recurrent Vulvovaginal Candidiasis. NEJM Evid. 2022;1(8):EVIDoa2100055. doi:10.1056/EVIDoa2100055
  10. Goje O, Azie NE, Angulo DA, et al. A phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp to reduce the incidence of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2025;233(6):617.e1-617.e18. doi:10.1016/j.ajog.2025.07.040
  11. Brand SR, Sobel JD, Nyirjesy P, et al. A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis. Clin Infect Dis. 2021;73(7):e1518-e1524. doi:10.1093/cid/ciaa1204
  12. Iavazzo C, Gkegkes ID, Zarkada IM, Falagas ME. Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence. J Womens Health (Larchmt). 2011;20(8):1245-1255. doi:10.1089/jwh.2010.2708
  13. Akinosoglou K, Livieratos A, Asimos K, et al. Fluconazole-Resistant Vulvovaginal Candidosis: An Update on Current Management. Pharmaceutics. 2024;16(12):1555. doi:10.3390/pharmaceutics16121555
  14. Gardella B, Dominoni M, Cassani C, et al. Treatment of uncomplicated vulvovaginal candidiasis: topical or oral drugs? Single-day or multiple-day therapy? A network meta-analysis of randomized trials. Am J Obstet Gynecol. 2025;233(3):152-161. doi:10.1016/j.ajog.2025.03.031
  15. Slavin MB, Benrubi GI, Parker R, et al. Single dose oral fluconazole vs intravaginal terconazole in treatment of Candida vaginitis. Comparison and pilot study. J Fla Med Assoc. 1992;79(10):693-696. PMID 1460451
  16. Mikamo H, Matsumizu M, Nakazuru Y, et al. Efficacy and safety of a single oral 150 mg dose of fluconazole for the treatment of vulvovaginal candidiasis in Japan. J Infect Chemother. 2015;21(7):520-526. doi:10.1016/j.jiac.2015.03.011
  17. Patel DA, Gillespie B, Sobel JD, et al. Risk factors for recurrent vulvovaginal candidiasis in women receiving maintenance antifungal therapy: results of a prospective cohort study. Am J Obstet Gynecol. 2004;190(3):644-653. doi:10.1016/j.ajog.2003.11.027
  18. Crouss T, Sobel JD, Smith K, Nyirjesy P. Long-Term Outcomes of Women With Recurrent Vulvovaginal Candidiasis After a Course of Maintenance Antifungal Therapy. J Low Genit Tract Dis. 2018;22(4):382-386. doi:10.1097/LGT.0000000000000413
  19. Xie HY, Feng D, Wei DM, et al. Probiotics for vulvovaginal candidiasis in non-pregnant women. Cochrane Database Syst Rev. 2017;11(11):CD010496. doi:10.1002/14651858.CD010496.pub2
  20. Abbott J. Clinical and microscopic diagnosis of vaginal yeast infection: a prospective analysis. Ann Emerg Med. 1995;25(5):587-591. doi:10.1016/s0196-0644(95)70168-0
  21. U.S. National Library of Medicine, DailyMed. DIFLUCAN (fluconazole) tablet; DIFLUCAN (fluconazole) powder, for suspension. Prescribing information. Updated April 2, 2026. Accessed November 7, 2026. DailyMed label
  22. Phillips NA, Rocktashel M, Merjanian L. Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy. Drug Des Devel Ther. 2023;17:363-367. doi:10.2147/DDDT.S339349
  23. Hussen I, Aliyo A, Abbai MK, Dedecha W. Vaginal candidiasis prevalence, associated factors, and antifungal susceptibility patterns among pregnant women attending antenatal care at bule hora university teaching hospital, Southern Ethiopia. BMC Pregnancy Childbirth. 2024;24(1):619. doi:10.1186/s12884-024-06844-x
  24. Chayachinda C, Thamkhantho M, Rekhawasin T, Klerdklinhom C. Sertaconazole 300 mg versus clotrimazole 500 mg vaginal suppository for treating pregnant women with acute vaginal candidiasis: a double-blinded, randomized trial. BMC Pregnancy Childbirth. 2024;24(1):235. doi:10.1186/s12884-024-06440-z
  25. U.S. National Library of Medicine, DailyMed. VIVJOA (oteseconazole) capsules. Prescribing information, revised 4/2022; DailyMed version updated January 8, 2026. Accessed November 7, 2026. DailyMed label
  26. U.S. National Library of Medicine, DailyMed. BREXAFEMME (ibrexafungerp tablets). Prescribing information, revised 11/2025 (version 12). Accessed November 7, 2026. DailyMed label
  27. Centers for Disease Control and Prevention. Diseases Characterized by Vulvovaginal Itching, Burning, Irritation, Odor, or Discharge. Sexually Transmitted Infections Treatment Guidelines, 2021. Last reviewed July 22, 2021. Accessed November 7, 2026. CDC guideline page
  28. Centers for Disease Control and Prevention. Bacterial Vaginosis. Sexually Transmitted Infections Treatment Guidelines, 2021. Last reviewed July 22, 2021. Accessed November 7, 2026. CDC guideline page
  29. Centers for Disease Control and Prevention. Symptoms of Diabetes. Last reviewed May 15, 2024. Accessed November 7, 2026. CDC page
  30. Nyirjesy P, Sobel JD. Genital mycotic infections in patients with diabetes. Postgrad Med. 2013;125(3):33-46. doi:10.3810/pgm.2013.05.2650

About the Author

Parth Bhavsar, MD

Dr. Bhavsar is a board-certified family medicine physician and founder of TeleDirectMD. He evaluates vulvovaginal candidiasis with attention to the correct diagnosis, underlying risk factors such as diabetes and antibiotic use, and evidence-based treatment and prevention. He practices telemedicine across 40+ U.S. states and DC and is fluent in English, Hindi, Gujarati, and Urdu.

Medically reviewed by Parth Bhavsar, MD. Last reviewed September 8, 2026.